ProCE Banner Activity

Maximizing Efficacy, Minimizing Risk: New Biomarkers and Ongoing Challenges With ICIs

Clinical Thought
Gain new insights on how to leverage tumor mutational burden to select patients most likely to benefit from ICI-based therapy and on ongoing challenges to optimize management of immune-related adverse events.

Released: November 30, 2020

Expiration: November 29, 2021

No longer available for credit.

Share

Faculty

Marianne Davies

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Professor
Coordinator of Oncology Concentration

Yale University School of Nursing
Oncology Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Professor
Coordinator of Oncology Concentration

Yale University School of Nursing
Oncology Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP, has disclosed that she has received fees for non-CME/CE services from Genentech and Merck.

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho and salary from Caris and Indivumed.